Breaking news from “The Pink Sheet” DAILY
Executive Summary
Visit 1www.ThePinkSheetDAILY.com for coverage of the latest developments in the pharmaceutical industry, including the approval of Bristol-Myers Squibb/Otsuka's antipsychotic Abilify for use in acute bipolar mania, J&J's subpoena from the HHS Inspector General requesting documents relating to its sales and marketing of Procrit and Gov. Schwarzenegger's vetoes of California importation legislation. To sign up for a free trial of "The Pink Sheet" DAILY, visit our website or call customer service at 800-332-2181...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.